STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

USANA Health Sciences insider plans $106k stock sale under Rule 144

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

USANA Health Sciences (USNA) filed a Form 144 indicating an insider’s intent to sell 3,515 common shares through Morgan Stanley Smith Barney on or after 30 Jul 2025. The shares have an aggregate market value of $106,364, based on the filing date, and represent roughly 0.02 % of the company’s 18.6 million shares outstanding.

The stock being sold was acquired as restricted-stock awards: 1,138 shares granted on 4 Feb 2022 and 2,377 shares granted on 6 Feb 2025. No prior insider sales were reported in the past three months, and the filer affirms possession of no undisclosed material adverse information.

The transaction is modest relative to USNA’s float and appears to be a routine liquidity event rather than a signal of fundamental change. Nevertheless, investors often monitor Form 144 filings for potential sentiment shifts among insiders.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Small insider sale (~0.02% float) is routine; negligible fundamental impact.

At just over $106k, the proposed disposition of 3,515 shares looks de-minimis for a $1.3 bn-market-cap company. The shares stem from standard equity compensation grants and are moving through a major broker, suggesting an orderly sale. Insider activity can hint at sentiment, but the absence of additional recent sales or adverse disclosures limits interpretive value. I rate the filing neutral to share-price fundamentals.

TL;DR: Filing signals compliance; volume too small to raise governance red flags.

The filer followed Rule 144 disclosure, indicating awareness of reporting obligations. No aggregation of related-party sales is required, and the representation affirms no undisclosed material info, mitigating litigation risk. Volume sold is immaterial, so governance concerns are minimal. Overall, this is standard housekeeping rather than a directional cue.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Usana Health Sciences Inc

NYSE:USNA

USNA Rankings

USNA Latest News

USNA Latest SEC Filings

USNA Stock Data

374.57M
10.42M
42.93%
61.22%
3.86%
Packaged Foods
Medicinal Chemicals & Botanical Products
Link
United States
SALT LAKE CITY